The first major distinction is non-muscle-invasive versus muscle-invasive disease
Freiburg and Düsseldorf describe transurethral bladder-tumor resection as both a diagnostic and treatment step for selected tumors limited to the bladder lining. More aggressive or recurrent non-muscle-invasive disease may require intravesical treatment such as BCG, while muscle-invasive disease can require a very different treatment pathway.
Radical cystectomy is not the starting point for every bladder tumor
Heidelberg, Freiburg, Düsseldorf and Essen document radical cystectomy for selected invasive or otherwise high-risk bladder cancers. The indication depends on the exact pathology, depth of invasion, prior local treatment and the wider oncologic plan. Patients should not interpret the availability of robotic cystectomy as proof that bladder removal is necessary for their case.
Urinary diversion is part of the treatment decision
When the bladder is removed, a new route for urine is required. German centers describe options such as an ileal conduit and selected continent or orthotopic reconstructions. The suitable option depends on tumor anatomy, kidney function, bowel and general health, urethral involvement, prior treatment and the patient's ability to manage the diversion after discharge.
Systemic treatment may be part of the pathway
For muscle-invasive, locally advanced or metastatic disease, German bladder-cancer centers document perioperative chemotherapy, immunotherapy and other systemic oncology approaches alongside surgery. The sequence should be decided by the treating urology/oncology team rather than by choosing surgery in isolation.
Records to send before travelling
A useful remote review should allow the German team to confirm both the diagnosis and the treatment stage.
- TURBT / TUR-B operative report and pathology
- Tumor grade, stage and presence or absence of muscle in the specimen
- Carcinoma in situ information when available
- Previous BCG or intravesical chemotherapy and response
- CT or MRI staging images in DICOM format
- Previous cystoscopy findings
- Kidney function and major laboratory results
- Prior pelvic radiotherapy or surgery
- Current medication, anticoagulants and major comorbidities
- A clear question about bladder preservation, cystectomy, systemic therapy or second opinion
Plan follow-up before returning home
Bladder cancer commonly requires structured surveillance after local treatment, and major surgery requires long-term follow-up of urinary diversion, kidney function and possible complications. Ask which cystoscopy, imaging, laboratory or stoma/neobladder checks must occur in Germany and which can be transferred to the home-country team.
Official sources
Sources last checked 2026-08-30. Confirm current eligibility, procedure details and hospital requirements directly with the treating urology team.
- Bladder cancer – diagnostics and treatment spectrum — University Medical Center Freiburg ↗
- Bladder cancer center – diagnostic and therapeutic priorities — University Hospital Düsseldorf ↗
- Bladder cancer and Da Vinci radical cystectomy — Heidelberg University Hospital ↗
- Bladder cancer treatment — University Hospital Essen ↗